- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
What We're Reading: Antibiotic Misuse Fuels Rise of Drug-Resistant Superbugs
What we're reading, November 17, 2015: misunderstanding of antibiotics has fueled the rise of drug-resistant superbugs; healthcare leaders overwhelmingly support government intervention to curb rising cost of drugs; and the FDA wants more regulation on laboratory-developed tests.
Misuse of Antibiotics Fueling Rise of Drug-Resistant Superbugs
Confusion over the role antibiotics play and when to take them has fueled the rise of drug-resistant superbugs, according to the World Health Organization. The United Nations found that 64% of people believe that penicillin-based drugs and other antibiotics can treat colds and the flu, despite the fact that they have no impact on viruses, reported Reuters. This overuse can lead to resistance that exacerbates the development of drug-resistant bacteria.
Healthcare CEOs Support Government Intervention in Rising Drug Costs
Consumers aren’t the only ones looking to government intervention to curb the rising cost of drug prices: 86% of healthcare leaders favor the federal government taking a bigger role, according to Modern Health’s CEO Power Panel survey. The respondents supported giving the government the ability to negotiate drug prices for Medicare and Medicaid. Nearly 60% of respondents rejected the claim from drugmakers and their supporters that higher prices are reflect research and development costs and the fact that most experimental drugs never make to the market, Modern Healthcare reported.
FDA Calls for More Regulation on Laboratory-Developed Tests
The FDA is calling for more regulation on certain laboratory-developed tests, which may cause harm to patients by producing erroneous results, The Wall Street Journal reported. The FDA released a report on laboratory-developed tests ahead of a House Energy and Commerce subcommittee evaluation for possible legislation limiting the FDA’s regulatory powers. The agency is contending that it needs to regulate these tests to ensure clinical accuracy, but officials in the industry worry FDA regulation stymies innovation.
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
